Clinical Trial Update: A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

This clinical trial update indicates that a Phase 2 neoadjuvant study of Sutent (sunitinib) for renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED